investigation
SIM0725 has been approved by the National Medical Products Administration to conduct clinical trials in China.
A investigation by 先聲藥業集團. Statements are as reported by the cited publishers — not verified by DecisionGateway.
已獲國家藥品監督管理局批准在中國開展臨牀試驗
Discussion
Related claims
SIM0725 was independently developed by the company.先聲藥業集團 · statementSIM0725 is a long-acting antagonistic monoclonal antibody targeting the interleukin-2 receptor beta chain (CD122).先聲藥業集團 · statementSIM0725 is intended for the treatment of autoimmune diseases.先聲藥業集團 · statementSimcere Pharmaceutical has partnered with Germany's Vivoryon to develop SIM0408 in China, targeting neurotoxic amyloid N3pE, and it has been approved by the CDE to enter clinical trials.post author · statementThe self-developed SHR-3201 injection has been approved by the National Medical Products Administration to conduct clinical trials, and it is intended for Alzheimer's disease.post author · statementNovo Nordisk announced that the marketing application for its new drug CagriSema (cagrilintide and semaglutide injection) for long-term weight management has been accepted by the National Medical Products Administration.诺和诺德 · statement
More claims by 先聲藥業集團
SIM0725 was independently developed by the company.statementSIM0725 is a long-acting antagonistic monoclonal antibody targeting the interleukin-2 receptor beta chain (CD122).statementSIM0725 is intended for the treatment of autoimmune diseases.statement
All claims by 先聲藥業集團